GlassScriptPhysician profile
Shawn Raja Shekar
NPI 1558935353
$1,644.41
in general payments reported to CMS, 2019-2025
14 companies · $522 in 2025
The $522 reported for 2025 was more than what 79% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $416 · 2024: $706 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $441.28 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $283.15 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $226.33 | 2024-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $130.51 | 2023-2024 | Auvelity |
| Almatica Pharma LLC | $125.07 | 2023-2025 | Loreev Xr |
| Otsuka America Pharmaceutical, INC. | $103.09 | 2023-2024 | Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $101.80 | 2024 | Spravato, Invega Sustenna |
| Alkermes, INC. | $62.42 | 2023 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $45.96 | 2024 | Cobenfy |
| Indivior INC. | $40.54 | 2023-2024 | Sublocade |
| Lundbeck LLC | $33.18 | 2023 | Rexulti |
| Orexo US, INC. | $19.30 | 2023 | Zubsolv |
| Ironshore Pharmaceuticals INC. | $17.80 | 2023 | Jornay Pm |
| Octapharma USA, INC. | $13.98 | 2025 | Panzyga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawn Shekar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.